ARA-290 (Cibinetide)
An erythropoietin-derived peptide (cibinetide) studied in clinical trials for small-fiber neuropathy; investigational, not approved.
What it is
ARA-290, or cibinetide, is an 11-amino-acid peptide engineered from erythropoietin — designed to keep EPO's tissue-protective signaling while discarding its red-blood-cell effects. Unusually for the gray market's catalog, it has a genuine clinical-trial history.
Phase 2 trials studied it for painful small-fiber neuropathy in sarcoidosis and diabetes, with encouraging but not definitive results, and development never reached approval. It remains investigational everywhere — which makes online 'cibinetide' another case of trial-stage science bottled early.
What researchers have actually studied it for
Painful small-fiber neuropathy — particularly in sarcoidosis — in real phase 2 clinical trials; development stopped short of approval.
How it works
It selectively targets the innate repair receptor — a complex of the EPO receptor and CD131 that appears on stressed tissue — activating anti-inflammatory, tissue-protective programs without stimulating red-blood-cell production. That selectivity was the whole design goal.
The molecule itself
An 11-amino-acid peptide engineered from erythropoietin's helix-B surface — the tissue-protective face of EPO, isolated from the hematopoietic face. It targets the innate repair receptor (EPOR/CD131 complex) that stressed tissue displays, without touching red-blood-cell production.
Where it came from
Developed by Araim Pharmaceuticals from research into why EPO protected tissue beyond blood counts, cibinetide advanced through phase 2 in the 2010s for sarcoidosis-associated small-fiber neuropathy, earning orphan designations along the way. Development slowed short of phase 3 success, and the gray market picked up the name.
The timeline
2000s
EPO's non-blood tissue protection mapped; Araim founded to exploit it.
2010s
Phase 2 trials in sarcoidosis small-fiber neuropathy report corneal-nerve and symptom improvements.
2010s
Orphan designations granted; diabetes-neuropathy studies add mixed signals.
late 2010s+
Development slows short of phase 3; gray market adopts the name.
What the research record actually contains
- Phase 2 trials in sarcoidosis small-fiber neuropathy: improvements in corneal nerve-fiber measures and symptom scores.
- Diabetes neuropathy and other early studies with mixed, encouraging signals.
- No phase 3 success, no approval, no established clinical role yet.
What could change this assessment
The innate-repair-receptor concept remains scientifically alive; whether cibinetide itself gets a completed program depends on sponsorship economics. Neuropathy medicine would welcome it — the market's rare case of a gray-market compound with a genuinely open scientific future.
What's known about risks
Trial safety was reasonable in studied doses and durations — a genuinely better data position than most of this library. Long-term safety and real-world unsupervised use remain uncharacterized.
Where it stands legally
Investigational; no approval anywhere; not lawfully sold for human use.
Worth asking a licensed provider
- 1.If small-fiber neuropathy is my issue, has it actually been diagnosed and staged?
- 2.What evaluated treatments exist for my neuropathy before an investigational peptide?
- 3.Is any legitimate trial of cibinetide or successors open to me?
Common claims, corrected
“It's EPO-lite for performance.”
Reality: It was engineered specifically to lack EPO's blood effects — no oxygen-carrying benefit exists to abuse, which is the one athletic fact about it.
“Trial history means it's basically proven.”
Reality: Phase 2 signals without phase 3 success is medicine's most crowded graveyard tier — encouraging and unfinished are both true.
ARA-290 (Cibinetide) FAQ
What is ARA-290 used for?
In trials: small-fiber neuropathy pain, especially in sarcoidosis. Online it's marketed far more broadly — 'nerve repair' claims that outrun its actual phase 2 record.
Is ARA-290 approved anywhere?
No. It earned orphan-drug designations and completed phase 2 studies, but never reached approval in any country.
Does ARA-290 affect red blood cells like EPO?
By design, no — it was engineered to keep EPO's tissue-protective signaling without the blood effects, which is also why it isn't an athletic doping agent in the EPO sense.
What is small-fiber neuropathy?
Damage to the thin nerve fibers carrying pain and autonomic signals — burning pain with often-normal standard tests. It's the defined condition ARA-290's real trials targeted, and it deserves diagnosis, not self-treatment.
Why did development stall?
The public record suggests funding and program economics more than scientific failure — a common fate for small-sponsor orphan candidates, and a different signal than a failed trial.